Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
September 19, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household membersThis is the first time that any antiviral used in the treatment...
Ipsos : Investissement du fonds Lac1
September 17, 2024 01:50 ET
|
IPSOS
Investissement du fonds Lac1 Paris, 17 septembre 2024 – Le Conseil d’administration d’Ipsos considère que la décision du fonds Lac1 de devenir un actionnaire important et de long terme de la...
Ipsos: Investment of the Lac1 fund
September 17, 2024 01:50 ET
|
IPSOS
Investment of the Lac1 fund Paris, 17 September 2024 – The Board of Directors of Ipsos welcomes the decision of the Lac1 fund to become a major long-term shareholder in the company. The...
Global Zirconia Based Dental Ceramics Market is Expected to Grow at a CAGR of 9.1% over the Forecast Period (2024 – 2034): A Report by TNR, The Niche Research
September 16, 2024 15:32 ET
|
The Niche Research
Wilmington, Delaware, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Zirconia based dental ceramics are advanced materials used in dentistry, primarily composed of zirconium dioxide (ZrO₂). These ceramics are...
Les résultats finaux de l’essai de Phase III CABINET corroborent les bénéfices en termes d’efficacité de Cabometyx® dans les tumeurs neuroendocrines avancées
September 16, 2024 08:45 ET
|
Ipsen Pharma
Les données ont démontré une réduction significative, tant sur le plan statistique que sur le plan clinique, du risque de progression de la maladie ou de décès avec Cabometyx® (cabozantinib) par...
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
September 16, 2024 08:45 ET
|
Ipsen Pharma
Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx® (cabozantinib) versus placebo in advanced pancreatic and...
Ipsen communique de nouvelles données sur l’essai de Phase III CONTACT-02 dans le cancer de la prostate métastatique résistant à la castration au terme de l’analyse finale de la survie globale
September 15, 2024 08:45 ET
|
Ipsen Pharma
L’essai portant sur Cabometyx® (cabozantinib) en association avec l’atézolizumab a démontré une tendance positive à l’amélioration de l’un des critères d’évaluation principaux de la survie globale,...
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
September 15, 2024 08:45 ET
|
Ipsen Pharma
Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints of overall survival, but did not meet...
Rogers offrira les tout nouveaux iPhone 16, iPhone 16 Plus, iPhone 16 Pro, iPhone 16 Pro Max, Apple Watch Series 10, Apple Watch Ultra 2 en titane noir et AirPods 4
September 13, 2024 08:00 ET
|
Rogers Communications Canada Inc.
TORONTO, 13 sept. 2024 (GLOBE NEWSWIRE) -- Rogers proposera iPhone 16 et iPhone 16 Plus, pensés pour Apple Intelligence1 et dotés de la toute nouvelle puce A18. Les deux modèles offrent la...
Moment Factory Speeds Up Its Global Expansion With An Ambitious Growth Plan
September 12, 2024 07:00 ET
|
Moment Factory
Montreal, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Moment Factory, a global leader in multimedia entertainment, is set to redefine the immersive experience industry with a dynamic growth plan that...